Samantha L Allison1, Thomas L Rodebaugh1, Chiharu Johnston1, Anne M Fagan2,3,4, John C Morris2,4, Denise Head1,2,5. 1. Department of Psychological and Brain Sciences, Washington University in St. Louis, St. Louis, Missouri, USA. 2. Knight Alzheimer Disease Research Center, Washington University in St. Louis, St. Louis, Missouri, USA. 3. Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, Missouri, USA. 4. Neurology Department, Washington University in St. Louis, St. Louis, Missouri, USA. 5. Radiology Department, Washington University in St. Louis, St. Louis, Missouri, USA.
Abstract
OBJECTIVE: There remains a need for a non-invasive and cost-effective screening measure that could be administered prior to the provision of a lumbar puncture or positron emission tomography scan for the detection of preclinical Alzheimer disease (AD). Previous findings suggest that a hippocampally-based spatial navigation task may be effective for screening individuals for the preclinical AD continuum (i.e., low cerebrospinal fluid (CSF) Aβ42). Unfortunately, this task took 1.5-2 hours to administer, which would be time-prohibitive in a clinical setting. Therefore, the goal of this study was to compare psychometric properties of six spatial navigation-related tasks in order to take the next steps in developing a clinically appropriate screening measure. METHODS: Psychometric properties (i.e., reliability, diagnostic accuracy, validity) of a modified version of the cognitive mapping task, two binding tasks, a visual perspective taking task, and self- and informant report versions of a questionnaire were examined in a sample of 91 clinically normal (CN) individuals. CSF Aβ42 and ptau181 were available for 30 individuals. RESULTS: The learning phase of the cognitive mapping task and the self-report questionnaire were sensitive to identifying individuals in the preclinical AD continuum (93% and 87% sensitivity, 60% and 67% specificity, respectively). These two measures also demonstrated good test-retest stability (intraclass correlation coefficients = .719 and .838, respectively) and internal consistency (Cronbach's αs = .825 and .965, respectively). CONCLUSIONS: These findings suggest that a self-report questionnaire and aspects of a cognitive mapping task may be particularly appropriate for development as screening tools for identifying individuals in the preclinical AD continuum.
OBJECTIVE: There remains a need for a non-invasive and cost-effective screening measure that could be administered prior to the provision of a lumbar puncture or positron emission tomography scan for the detection of preclinical Alzheimer disease (AD). Previous findings suggest that a hippocampally-based spatial navigation task may be effective for screening individuals for the preclinical AD continuum (i.e., low cerebrospinal fluid (CSF) Aβ42). Unfortunately, this task took 1.5-2 hours to administer, which would be time-prohibitive in a clinical setting. Therefore, the goal of this study was to compare psychometric properties of six spatial navigation-related tasks in order to take the next steps in developing a clinically appropriate screening measure. METHODS: Psychometric properties (i.e., reliability, diagnostic accuracy, validity) of a modified version of the cognitive mapping task, two binding tasks, a visual perspective taking task, and self- and informant report versions of a questionnaire were examined in a sample of 91 clinically normal (CN) individuals. CSF Aβ42 and ptau181 were available for 30 individuals. RESULTS: The learning phase of the cognitive mapping task and the self-report questionnaire were sensitive to identifying individuals in the preclinical AD continuum (93% and 87% sensitivity, 60% and 67% specificity, respectively). These two measures also demonstrated good test-retest stability (intraclass correlation coefficients = .719 and .838, respectively) and internal consistency (Cronbach's αs = .825 and .965, respectively). CONCLUSIONS: These findings suggest that a self-report questionnaire and aspects of a cognitive mapping task may be particularly appropriate for development as screening tools for identifying individuals in the preclinical AD continuum.
Authors: Joseph L Price; Daniel W McKeel; Virginia D Buckles; Catherine M Roe; Chengjie Xiong; Michael Grundman; Lawrence A Hansen; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Charles D Smith; Daron G Davis; Frederick A Schmitt; William R Markesbery; Jeffrey Kaye; Roger Kurlan; Christine Hulette; Brenda F Kurland; Roger Higdon; Walter Kukull; John C Morris Journal: Neurobiol Aging Date: 2009-04-18 Impact factor: 4.673
Authors: Ellen Grober; Charles B Hall; Richard B Lipton; Alan B Zonderman; Susan M Resnick; Claudia Kawas Journal: J Int Neuropsychol Soc Date: 2008-03 Impact factor: 2.892
Authors: Yuying Liang; Yoni Pertzov; Jennifer M Nicholas; Susie M D Henley; Sebastian Crutch; Felix Woodward; Kelvin Leung; Nick C Fox; Masud Husain Journal: Cortex Date: 2016-02-06 Impact factor: 4.027
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Martina Laczó; Lukas Martinkovic; Ondrej Lerch; Jan M Wiener; Jana Kalinova; Veronika Matuskova; Zuzana Nedelska; Martin Vyhnalek; Jakub Hort; Jan Laczó Journal: Front Aging Neurosci Date: 2022-06-02 Impact factor: 5.702
Authors: Taylor F Levine; Catherine M Roe; Ganesh M Babulal; Anne M Fagan; Denise Head Journal: Alzheimer Dis Assoc Disord Date: 2022 Jan-Mar 01 Impact factor: 2.357
Authors: Taylor F Levine; Samantha L Allison; Marta Stojanovic; Anne M Fagan; John C Morris; Denise Head Journal: Alzheimers Dement Date: 2020-02-11 Impact factor: 21.566
Authors: Matthew J Sodoma; Rachel C Cole; Taylor J Sloan; Chase M Hamilton; James D Kent; Vincent A Magnotta; Michelle W Voss Journal: Neuroimage Date: 2021-10-30 Impact factor: 6.556